DHAP (chemotherapy)
From Wikipedia, the free encyclopedia
DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory non-Hodgkin lymphoma and Hodgkin's lymphoma.[1] It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplantation. In combination with anti-CD20 monoclonal antibody rituximab (Rituxan, Mabthera) it is called R-DHAP or DHAP-R.
This article relies largely or entirely on a single source. (May 2021) |
[R]-DHAP regimen consists of:
- Rituximab, a monoclonal antibody, directed at B-cell surface antigen CD20
- (D)examethasone, a glucocorticoid hormone
- (H)igh-dose (A)ra-C - cytarabine, an antimetabolite;
- (P)latinol (cisplatin), a platinum-based antineoplastic, also an alkylating antineoplastic agent.